Prostaglandin F2 receptor negative regulatory factor (PTGFRN) can enhance drug delivery to tumor-associated macrophages (TAMs), and the PTGFRN-engineered EBPs effectively delivered STAT6-targeting ASO to TAMs and reprogrammed them into a proinflammatory M1 phenotype, which is beneficial for cancer treatment [58]. This evidence concerns the gene PTGFRN and neoplasm.